!"#$%&'()*+ , - ./!0123456789: 2025 ;<=>?@5AB C D#EFG 二零二五年九月 国浩律师（上海）事务所 关于天臣国际医疗科技股份有限公司 2025 年第三次临时股东会之 法律意见书 致：天臣国际医疗科技股份有限公司 天臣国际医疗科技股份有限公司（以下简称"公司"）2025 年第三次临时股 东会于 2025 年 9 月 12 日召开。国浩律师（上海）事务所（以下简称"本所"） 经公司聘请，委派律师出席现场会议，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）等法律、 法规及中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股东会规 则》和《天臣国际医疗科技股份有限公司章程》（以下简称"《公司章程》"），就 本次股东会的召集、召开程序、出席大会人员资格、会议表决程序等事宜发表法 律意见。 为出具本法律意见书，本所律师出席了本次股东会，审查了公司提供的有关 本次大会各项议程及相关文件，听取了公司董事会就有关事项所作的说明。 在审查有关文件的过程中，公司向本所律师保证并承诺，其向本所提供的文 件和所作的说 ...

天臣国际医疗科技股份有限公司（以下简称"公司"）第二届董事会第二十九 次会议于2025年9月12日以现场结合通讯的方式召开。会议通知已于2025年9月9 日通过书面及电话等方式送达全体董事。本次会议由董事长陈望宇先生召集并主 持，应出席会议董事7名，实际出席会议董事7名，本次会议的召集、召开及审议 程序符合《中华人民共和国公司法》及《天臣国际医疗科技股份有限公司章程》 的相关规定。 二、董事会会议审议情况 会议经与会董事审议并书面表决通过了如下议案： 1、审议通过《关于使用部分暂时闲置募集资金进行现金管理的议案》 董事会同意：公司在不影响募集资金投资项目建设、募集资金使用和正常业 务经营的前提下，使用最高额度不超过人民币2亿元（包含本数）的暂时闲置募 集资金进行现金管理，购买安全性高、流动性好、满足保本要求的现金管理产品， 使用期限自公司董事会审议通过之日起12个月内有效，在上述额度及期限内，资 金可循环滚动使用。本次使用暂时闲置募集资金进行现金管理事项无需提交股东 会审议。 证券代码：688013 证券简称：天臣医疗 公告编号：2025-055 天臣国际医疗科技股份有限公司 第二届董事会第二十九次会议决议公 ...

Group 1 - The company Tianchen Medical (688013.SH) plans to use no more than RMB 200 million of temporarily idle raised funds for cash management [1] - The usage period for the funds is valid for 12 months from the date of approval by the board of directors [1] - Within the specified limit and period, the funds can be used in a rolling manner [1]

Group 1 - The company Tianchen Medical (688013.SH) plans to use no more than RMB 200 million of temporarily idle raised funds for cash management [1] - The usage period for these funds is effective for 12 months from the date of approval by the board of directors [1] - Within the specified limit and timeframe, the funds can be used in a rolling manner [1]

Group 1 - Tianchen Medical's stock price increased by 3.6%, reaching 60.11 CNY per share, marking a new high [2] - The company's total market capitalization surpassed 4.878 billion CNY [2] - The trading volume amounted to 84.4529 million CNY [2]

Group 1 - The stock price of Tianchen Medical (688013) closed at 55.89 yuan on September 9, 2025, down by 1.91% with a turnover rate of 2.01% and a trading volume of 16,300 shares, resulting in a transaction amount of 91.7574 million yuan [1] - On September 9, the net inflow of main funds was 926,600 yuan, accounting for 1.01% of the total transaction amount, while retail funds had a net outflow of 38,700 yuan, representing 0.04% of the total transaction amount [1][3] - Tianchen Medical will participate in the 2025 semi-annual performance briefing for the medical device industry on September 17, 2025, where the company will address investor inquiries regarding its semi-annual operational results and financial status [1][3]

Core Viewpoint - Tianchen Medical announced its plan to participate in the 2025 semi-annual performance briefing for the medical device and equipment industry on September 17, 2025 [2] Company Summary - Tianchen Medical will attend the performance briefing, indicating its engagement with the industry and potential for future growth [2] Industry Summary - The event is part of a collective performance briefing for the medical device and equipment sector, highlighting the industry's focus on transparency and performance metrics [2]

证券代码：688013 证券简称：天臣医疗 公告编号：2025-053 会议召开方式：上证路演中心图文及网络文字互动 投资者可于 2025 年 09 月 10 日（星期三）至 09 月 16 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 tsbs@touchstone.hk）将需要了解和关注的问题提前提供给公司。公司将在说明 会上对投资者普遍关注的问题进行回答。 天臣国际医疗科技股份有限公司（以下简称"公司"或"天臣医疗"）于 2025 年 8 月 27 日在上海证券交易所网站（www.sse.com.cn）披露了《天臣医疗 2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 年半年度经营 成果、财务状况、发展理念，公司计划于 2025 年 09 月 17 日（星期三）15:00- 17:00 参加由上海证券交易所举办的 2025 年半年度科创板医疗器械及医疗设备 行业集体业绩说明会，就投资者关心的问题进行交流。 天臣国际医疗科技股份有限公司 关于召开 2025 年半年度科创板医疗器械及医疗设备 行业集体业绩说明会的公告 本公司董事会及全体董事保 ...

Company Overview - Tianchen Medical is located in Suzhou Industrial Park, Jiangsu Province, and was established on August 18, 2003. The company was listed on September 28, 2020. Its main business involves the research, innovation, production, and sales of high-end surgical staplers [1]. - The company operates in the pharmaceutical and biological industry, specifically in the medical devices and medical consumables sector. It is associated with concepts such as high dividends, buybacks, strong annual performance, margin financing, and specialized innovation [1]. Financial Performance - As of June 30, Tianchen Medical reported a revenue of 156 million yuan, representing a year-on-year growth of 17.66%. The net profit attributable to the parent company was 48.21 million yuan, showing a year-on-year increase of 67.10% [1]. - Since its A-share listing, Tianchen Medical has distributed a total of 171 million yuan in dividends, with 139 million yuan distributed over the past three years [2]. Stock Performance - On September 8, Tianchen Medical's stock price decreased by 2.15%, trading at 55.88 yuan per share, with a total transaction volume of 35.89 million yuan and a turnover rate of 0.78%. The company's total market capitalization is 4.535 billion yuan [1]. - Year-to-date, the stock price has increased by 236.02%. Over the last five trading days, it has decreased by 3.36%, while it has increased by 49.89% over the last 20 days and 104.91% over the last 60 days [1]. - As of the latest data, the number of shareholders is 4,148, a decrease of 6.64% from the previous period, while the average circulating shares per person increased by 7.11% to 19,564 shares [1]. Capital Flow - In terms of capital flow, there was a net outflow of 913,500 yuan from main funds, with large orders buying 3.92 million yuan (10.94% of total) and selling 4.84 million yuan (13.48% of total) [1].

Summary of Key Points Core Viewpoint - Tianchen Medical (688013) reported a closing price of 57.11 yuan on September 5, 2025, with a 3.93% increase and a trading volume of 23,700 shares, amounting to a total transaction value of 133 million yuan [1]. Trading Information - On September 5, the net outflow of main funds was 21.61 million yuan, accounting for 16.28% of the total transaction value [1][3]. - Retail investors had a net inflow of 24.49 million yuan, representing 18.44% of the total transaction value [1]. Company Announcements - Tianchen Medical plans to reappoint Gongzheng Tianye Accounting Firm as the auditing institution for the year 2025, which has 349 registered accountants and 81 listed company audit clients [1]. - The company intends to distribute a cash dividend of 5.00 yuan (including tax) for every 10 shares, totaling 40.33 million yuan, which represents 83.66% of the half-year net profit attributable to shareholders [1][3].